Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The Acute Effect of Resistance Exercise in Individuals With Hypertrophic Cardiomyopathy: A Pilot Study.

The American journal of cardiology·2026
Same author

Prevalence and Predictors of Cardiac Troponin Elevations Following Exercise: a Systematic Review, Meta-analysis, and Meta-regression.

European journal of preventive cardiology·2026
Same author

Sudden Cardiac Arrest in Athletes.

The New England journal of medicine·2026
Same author

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

European heart journal·2026
Same author

Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology.

Journal of the American College of Cardiology·2026
Same author

Syncope During Cycling.

JACC. Case reports·2026

Video Experimental Relacionado

Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

La miopatía asociada a las estatinas.

Paul D Thompson1, Priscilla Clarkson, Richard H Karas

  • 1Preventive Cardiology and Cardiovascular Research, Division of Cardiology, Hartford Hospital, Hartford, Conn 06102, USA. pthomps@harthosp.org

JAMA
|April 4, 2003
PubMed
Resumen
Este resumen es generado por máquina.

Las estatinas pueden causar problemas musculares, desde dolor leve hasta rabdomiolisis severa. Los factores de riesgo y las interacciones farmacológicas pueden aumentar estos efectos adversos, con mecanismos aún bajo investigación.

Videos de Experimentos Relacionados

Last Updated: Jul 6, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Área de la Ciencia:

  • Farmacología Farmacología.
  • Toxicología Toxicología.
  • La medicina clínica es la medicina clínica.

Sus antecedentes:

  • Las estatinas, inhibidores de la HMG-CoA reductasa, son ampliamente utilizadas para el control del colesterol.
  • Estos medicamentos están asociados con un espectro de quejas del músculo esquelético, que van desde mialgia hasta rabdomiolisis.
  • Comprender estos efectos adversos es crucial para la seguridad del paciente y la terapia eficaz para reducir los lípidos.

Objetivo del estudio:

  • Proporcionar un resumen clínico de la miopatía asociada a las estatinas.
  • Para discutir los posibles mecanismos subyacentes a la lesión muscular inducida por las estatinas.
  • Para actualizar los informes sobre la rabdomiolisis asociada a las estatinas utilizando datos de la FDA.

Principales métodos:

  • Revisión de la literatura de los artículos de miopatía por estatinas a través de PubMed (hasta noviembre de 2002).
  • Revisión de ensayos clínicos de estatinas, series de casos y revisiones (PubMed hasta enero de 2003).
  • Análisis de los informes de eventos adversos de MEDWATCH de la FDA para la rabdomiolisis asociada a las estatinas (enero de 1990 - marzo de 2002).

Principales resultados:

  • Los problemas musculares son raros en los ensayos clínicos de estatinas.
  • El sistema MEDWATCH de la FDA documentó 3339 casos de rabdomiolisis asociada a las estatinas, siendo la cerivastatina la más implicada.
  • Los datos sobre síntomas musculares menos graves (dolor, debilidad) sugieren una prevalencia del 1-5%; los factores de riesgo y las interacciones farmacológicas (por ejemplo, gemfibrozil) pueden exacerbar los efectos adversos.

Conclusiones:

  • La miopatía asociada a las estatinas abarca una serie de problemas musculares, incluida la rabdomiolisis rara pero grave.
  • Factores como la disfunción de órganos, comorbilidades e interacciones farmacológicas influyen significativamente en el riesgo de miopatía.
  • Si bien los mecanismos no están completamente esclarecidos, las estatinas pueden afectar el mantenimiento de los miocitos al reducir la producción de proteínas reguladoras.